CJC-1295 vs sermorelin: hormone changes are only part of the story

Author and reviewer: Dr. Sarah Chen, PhD Pharmacology.

Posted on 27 October 2026

CJC-1295 and sermorelin appear in discussions of growth-hormone-releasing hormone research. They should not be ranked as interchangeable “muscle” or “anti-ageing” treatments. The exact compound and the outcome measured in a study determine what a comparison can support.

What is sermorelin?

Sermorelin is a synthetic 29-amino-acid fragment corresponding to the amino-terminal portion of human growth-hormone-releasing hormone, commonly written GHRH(1–29)-amide. That identifies its structure; it does not establish that every product using the name is authorised for every proposed use. (NCBI PubChem, n.d.)

What did the CJC-1295 studies investigate?

Two randomised, placebo-controlled trials published in 2006 investigated a long-acting CJC-1295 analogue in healthy adults. They lasted 28 and 49 days and measured pharmacokinetics and growth hormone and IGF-I responses. The reported half-life was approximately 5.8–8.1 days. These were hormone and exposure findings, not demonstrations of better athletic performance or longer life. (Teichman et al., 2006)

Another 2006 study examined growth hormone pulsatility after administration of an albumin-binding, long-acting analogue. Its question concerned hormone secretion patterns. A claim about strength, injury recovery or anti-ageing would require different endpoints and an appropriate study population. (Ionescu & Frohman, 2006)

Why “with DAC” and “without DAC” cannot be ignored

A search result may shorten a name to CJC-1295 while leaving out a modification that matters to its behaviour. Do not attach the multi-day half-life from long-acting research to a product described as “without DAC” simply because part of the name matches. Check the exact sequence and modification in the source paper and the material being discussed. (Teichman et al., 2006)

Is a higher hormone level necessarily a benefit?

A biological response shows that something happened; its value depends on the clinical context. To assess a benefit claim, ask what participants could do or feel differently, how harms were measured and whether the result persisted. A laboratory value alone cannot answer all of those questions.

For example, “changed IGF-I” and “improved muscle function” should occupy separate rows in an evidence table. If only the first row has data, the second remains an unanswered question. The same reasoning applies to a claim about sleep, body composition or recovery.

Can the studies establish the effects of a combination?

Combining a GHRH-related compound with another peptide creates a new comparison. The presence of studies on individual components does not establish the outcome for their mixture. Look for research on the actual combination, rather than adding separate benefit claims together.

How should I use this comparison?

Use it to read research more accurately, not to choose a treatment or dosing schedule. A useful next paper would answer a specific question in a defined population with clinically meaningful outcomes. Until those details match, “better” is too broad a conclusion.